peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
Hansa Biopharma
HNSA (, %) SEK
Hansa Biopharma

Hansa Biopharma to host conference call to provide interim results for January-March 2023 and a Business Update

14 Apr 2023, 08:00

Lund, Sweden, April 14, 2023 Hansa Biopharma AB (Nasdaq Stockholm: HNSA) will publish its interim report for January-March 2023 at 8:00 CET on April 20, 2023. All interested parties are invited to participate in a telephone conference, which will include a presentation of the year-end results and a business update, on the same date at 14:00 CET/8:00am EST. The event will be hosted by Hansa Biopharma’s CEO, Søren Tulstrup, and CFO, Donato Spota, and the presentation will be held in English.

Slides used in the presentation will be live on the company website during the call under “Events & Presentations” and will also be made available online after the call. Link to presentation

To participate in the telephone conference, please use the dial-in details provided below:

Sweden: +46 10 884 80 16

United Kingdom: +44 20 3936 2999

United States: +1 646 664 1960

Participant access code: 574936

The webcast will be available on  https://events.q4inc.com/attendee/178799671

Financial calendar and events 2023

April 20, 2023                     Interim Report for January-March 2023

April 20, 2023                     Redeye Investor Forum, Gothenburg

April 21, 2023                     Redeye Lunch presentation, Stockholm

April 25, 2023                     Van Lanschot Kempen Life Sciences Conference 2023, Amsterdam

May 9, 2023                       Midcap Canada event (virtual)

May 11, 2023                     Erik Penser Company Day, Malmö

May 11, 2023                     Redeye Investor forum, Malmö

May 25, 2023                     Erik Penser Company Day, Stockholm

June 14, 2023                    Annual General Meeting

July 20, 2023                     Half-year Report for January-June 2023

Aug 24, 2023                     Erik Penser Company Day, Stockholm

Sept 7, 2023                      CITI Annual BioPharma Conference, Boston

Sept 11, 2023                    MorganStanley Global Healthcare Conference, NYC

Sept 14, 2023                    Pareto Annual Healthcare Conference, Stockholm

Oct 19, 2023                      Interim Report for January-September 2023

Nov 22, 2023                     Ökonomisk Ugebrev Life Science Event, Copenhagen

Files

For further information, please contact:

Klaus Sindahl, VP Head of Investor Relations
M: +46 (0) 709–298 269
E: klaus.sindahl@hansabiopharma.com

Stephanie Kenney, VP Global Corporate Affairs
M: +1 (484) 319 2802
E: stephanie.kenney@hansabiopharma.com

About Hansa Biopharma

Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa has developed a first-in- class immunoglobulin G (IgG) antibody cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa has a rich and expanding research and development program, based on the Company’s proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden and has operations in Europe and the U.S. The Company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at hansabiopharma.com.